Dual bronchodilation in COPD : lung function and patient-reported outcomes – a review by Price, David et al.
© 2017 Price et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of COPD 2017:12 141–168
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
141
R e v I e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/COPD.S116719
Dual bronchodilation in COPD: lung function and 





1Department of Primary Care 
Respiratory Medicine, Division 
of Applied Health Sciences, 
University of Aberdeen, Aberdeen, 
UK; 2Observational and Pragmatic 
Research Institute, Singapore; 
3Gransdalen Legesenter, Oslo, 
Norway; 4Department of Primary 
Care Research, University of 
Southampton, Southampton, 
UK; 5Department of Pulmonary 
Medicine, Hannover Medical School, 
Hannover, Germany
Abstract: Several fixed-dose combinations (FDCs) of long-acting bronchodilators (a long-acting 
muscarinic antagonist [LAMA] plus a long-acting β
2
-agonist [LABA]) are available for the 
treatment of COPD. Studies of these FDCs have demonstrated substantial improvements in lung 
function (forced expiratory volume in 1 second) in comparison with their respective constituent 
monocomponents. Improvements in patient-reported outcomes (PROs), such as symptoms and 
health status, as well as exacerbation rates, have been reported compared with a LABA or LAMA 
alone, but results are less consistent. The inconsistencies may in part be owing to differences in 
study design, methods used to assess study end points, and patient populations. Nevertheless, 
these observations tend to support an association between improvements in forced expiratory 
volume in 1 second and improvements in symptom-based outcomes. In order to assess the effects 
of FDCs on PROs and evaluate relationships between PROs and changes in lung function, we 
performed a systematic literature search of publications reporting randomized controlled trials 
of FDCs. Results of this literature search were independently assessed by two reviewers, with 
a third reviewer resolving any conflicting results. In total, 22 Phase III randomized controlled 
trials of FDC bronchodilators in COPD were identified, with an additional study including a 
post-literature search (ten for indacaterol–glycopyrronium once daily, eight for umeclidinium–
vilanterol once daily, three for tiotropium–olodaterol once daily, and two for aclidinium–
formoterol twice daily). Results from these studies demonstrated that the LAMA–LABA FDCs 
significantly improved lung function compared with their component monotherapies or other 
single-agent treatments. Furthermore, LABA–LAMA combinations also generally improved 
symptoms and health status versus monotherapies, although some discrepancies between lung 
function and PROs were observed. Overall, the safety profiles of the FDCs were similar to 
placebo. Further research is required to examine more closely any relationship between lung 
function and PROs in patients receiving LABA–LAMA combinations.
Keywords: chronic obstructive pulmonary disease, combination therapy, dyspnea, forced 
expiratory volume, health status, spirometry
Introduction
Appropriate pharmacological management of COPD involves treatment with inhaled 
bronchodilators to reduce airflow limitation and hyperinflation. Most patient groups 
identified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strat-
egy can be managed using long-acting inhaled bronchodilators (long-acting muscarinic 
antagonists [LAMAs] and long-acting β
2
-agonists [LABAs]), with or without inhaled 
corticosteroids.1 Fixed dose combinations (FDCs) provide potent bronchodilation versus 
single agents,2 with some advantage in terms of convenience and simplicity compared 
with combinations administered via separate inhalers. Beta agonists (BAs) and muscarinic 
antagonists (MAs) target different pathways to promote smooth-muscle relaxation and 
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inhibit pulmonary constriction. Combining bronchodilators 
with different modes of action appears to be additive, providing 
greater efficacy versus component monotherapies.3 Random-
ized controlled trials (RCTs) of LABA–LAMA combinations 
via separate inhalers have generally shown improved lung 
function versus component monotherapies.4–12
COPD is characterized by persistent airflow limitation, 
with forced expiratory volume in 1 second (FEV
1
) to forced 
vital capacity ratio and percentage predicted FEV
1
 widely 
used as pathophysiological markers.1 However, COPD is 
multidimensional, with pulmonary, extrapulmonary, and 
systemic effects. Outcomes in addition to FEV
1
 are needed 
to assess disease burden and treatment efficacy.13 Spirometry 
is central to COPD diagnosis, but does not measure COPD 
burden in terms of health status.14 Additionally, spirometry 
is not always performed, and symptoms and exacerbation 
history can play important roles in treatment initiation and 
management.15 It is therefore important that spirometry is 
accompanied by assessments using patient-reported outcome 
(PRO) measures, such as breathlessness, physical function-
ing, and health status.14 Minimal clinically important dif-
ferences (MCIDs) for these assessments and other COPD 
outcomes have been reviewed by Jones et al.14 Although 
a few studies and reports have examined associations 
between improved lung function (mainly FEV
1
) and PROs in 
COPD,16–21 the relationship between these efficacy measures 
is often weak, particularly for LAMAs and LABA–LAMA 
combinations. Here, we examine the evidence for the use 
of FDC bronchodilators in COPD, assess effects on PROs, 
and evaluate relationships between PROs and changes in 
lung function.
Materials and methods
This systematic literature search (not registered) was per-
formed in accordance with the general principles of the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA).22 The literature search identi-
fied primary, English-language, RCT publications of fixed-
combination bronchodilators reporting treatment effects on 
lung function and/or PROs in comparison with placebo, 
bronchodilator monotherapy, or inhaled corticosteroid–
LABA combinations in patients with COPD (Table S1). 
Data sources included a ProQuest search of Biosis, Biosis 
previews, Embase and Medline databases (January 1, 2006 
to July 31, 2014), and abstracts from principal respiratory 
congresses (January 1, 2009 to May 20, 2015; Table S2). 
These selected search dates ensured that all relevant publica-
tions on fixed-combination bronchodilators were captured. 
Following the publication-database searches and during 
preparation of this manuscript (August 2015 onward), addi-
tional relevant articles became available, and thus these were 
added to the literature-search results.
All search results were extracted and gathered by a single 
party. Titles and abstracts were then scrutinized in parallel 
by two independent reviewers, and papers were categorized 
as relevant (where both reviewers categorized a paper as 
“relevant”), not relevant (where both reviewers judged a 
paper as “not relevant”), or potentially relevant (where one 
reviewer judged a paper as “relevant” and the other judged 
the same paper as “not relevant”). Irrelevant publications/
studies comprised review papers, unapproved treatment 
doses, nonclinical trials, incorrect drug, or incorrect disease. 
Conflicting results were resolved by a third reviewer, who 
provided input as to whether the abstract was of potential 
relevance based on the same criteria as the first reviewers. 
To reduce the risk of omitting relevant studies/papers, all 
relevant and potentially relevant results were subsequently 
reviewed by the authors, who had the final decision regarding 
which publications to take to the next review level. Where 
relevance was not discernible from abstracts, full copies of 
author-confirmed relevant/potentially relevant articles were 
further assessed by two reviewers and conflicts resolved 
by a third reviewer. Data from the literature describing 
treatment differences with the FDC and comparator are 
summarized – according to end point – using least-squares 
mean (LSM) and 95% confidence interval (95% CI), odds 
ratio (OR), rate ratio, or hazard ratio (HR).
Results
Systematic literature-search results
The searches yielded 729 records, from which 35 primary 
publications were relevant (Figure 1). Literature searches 
were supplemented with information from ClinicalTrials.gov, 
and author expertise/knowledge (eg, if authors were aware 
that important publications were missing from search 
results).23 Between the time of the predefined search end 
(July 2014 for published manuscripts and May 2015 for con-
gress abstracts) and the drafting of this manuscript (August 
2015 onwards), additional FDC studies were being published, 
and are thus included in this review.23–34
Trials of fixed-dose dual-combination 
bronchodilators
FDC bronchodilators approved or in advanced clinical 
development for COPD include: indacaterol–glycopyrronium 
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LAMA–LABA Fev1 and patient-reported outcomes
International AG, Basel, Switzerland), umeclidinium–
vilanterol 110/50 µg OD (Laventair/Anoro® Ellipta®; 
GlaxoSmithKline PLC, London, UK), tiotropium–olodaterol 
OD (Spiolto® Respimat®; Boehringer Ingelheim, Ingelheim, 
Germany), aclidinium–formoterol twice daily (bis in die 
[BID]; Duaklir® Genuair®; AstraZeneca PLC, London, UK) 
and glycopyrrolate–formoterol (PT003; AstraZeneca).
Indacaterol–glycopyrronium OD is approved in 70 
countries. Of 13 large Phase III trials of indacaterol–glycopy-
rronium, publications are available for ten (SHINE, ILLUMI-
NATE, BRIGHT, ENLIGHTEN, SPARK, BLAZE, BEACON, 
LANTERN, QUANTIFY, and FLAME), all of which report 
lung function and PRO data and are included in this review 
(Table 1).2,24–26,35–40 These active-comparator and placebo-
controlled trials ranged from 3 to 64 weeks in duration.
Umeclidinium–vilanterol 62.5/25 µg OD is approved 
in the US and EU (higher doses are not reviewed here). 
Findings from 12 Phase III trials had been reported in pub-
lications or conference abstracts at the time of the literature 
search, including: five 24-week studies,23,32,41 seven 12-week 
studies,27,33,42,43 and one 52-week safety study (125/25 µg).45 
Lung-function and PRO data have been fully reported for 
six of the eight trials listed in Table 1.23,27,32,41
Tiotropium–olodaterol (5/5 µg; lower doses are not 
reviewed) OD has been approved in more than 20 European 
countries, the US, Canada, and Australia since May 2015. 
Results from two 1-year studies with tiotropium–olodaterol 
5/5 µg (included in this review; Table 1) have been reported 
and include data on lung function and health status versus 
the monocomponents.30 Results from an additional Phase III 
trial evaluating lung function and volume (VIVACITO) have 
been published (Table 1),31 two Phase III trials have been 
presented as abstracts,34,45 one further Phase III study has been 
completed (ClinicalTrials.gov NCT01536262) and four are 
ongoing (ClinicalTrials.gov NCT02006732, NCT01964352, 
NCT01969721, and NCT02085161).
Aclidinium–formoterol (400/12 µg BID) is approved 
in the EU. Findings from two of four Phase III trials have 
been fully reported comparing the combination therapy 
versus monocomponents or placebo, and are included in 
this paper (Table 1).28,29,46 Results from a 24-week Phase III 
study comparing aclidinium–formoterol with salmeterol–
fluticasone combination (SFC) BID had been published 
in abstract form at the time of the literature search.47 For 
glycopyrrolate–formoterol (in late-stage development), only 
Phase II congress abstracts are available.48–50 Three Phase 
III studies are ongoing (ClinicalTrials.gov NCT01854645, 
NCT01854658, and NCT01970878).
In this review, we focus on the 23 aforementioned pub-
lished Phase III RCTs and listed in Table 1 (supplemented 
with results presented at major respiratory congresses, where 
applicable): ten with indacaterol–glycopyrronium OD, eight 
with umeclidinium–vilanterol OD, three with tiotropium–
olodaterol OD, and two with aclidinium–formoterol BID. 
The remaining primary publications from the literature search 
were excluded, due to duplicate publications of the same 
results (eg, where a primary publication superseded several 
congress abstracts).
Patient population and study design
Patient populations, inclusion criteria, treatment blinding, 
and other characteristics differed between trials (Table 1). 
The majority of indacaterol–glycopyrronium OD studies 
enrolled symptomatic patients with moderate-to-severe air-
flow limitation (GOLD 2008, 2009, or 2010 classification), 
except for SPARK and FLAME, which enrolled patients 
with severe-to-very-severe or moderate-to-very-severe dis-
ease, respectively, and one or more exacerbations in the past 
year.2,24,26,35–40 The eight umeclidinium–vilanterol OD trials 
enrolled patients with moderate-to-severe or moderate-to-
very-severe COPD who were symptomatic.23,27,32,41 Patients 
in the tiotropium–olodaterol OD studies had moderate-to-
very-severe COPD.30,31 The aclidinium–formoterol BID 








Figure 1 Flowchart of systematic literature search.
Notes: Reasons for exclusion comprised: not a primary publication or not containing 
novel data from clinical studies, non-COPD study, data not from a randomized 
clinical study, medication not combination LABA–LAMA bronchodilator treatment, 
and unapproved dose for a licensed combination therapy.
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Across eight trials (3–64 weeks), indacaterol–glycopyrronium 
OD provided significant LSM treatment differences in trough 
FEV
1
 of 60–80 mL versus tiotropium 18 µg, 70–80 mL 
versus indacaterol 150 µg or glycopyrronium 50 µg alone, 
68 mL versus tiotropium + formoterol 18/12 µg, 62–72 mL 
versus SFC 50/500 µg BID, and 189–200 mL versus pla-
cebo (Table 2).2,24–26,35,36,39,40 Preliminary data suggest that the 
extent of FEV
1
 improvement may vary: in a post hoc analysis 
of SHINE, data from patients in the spirometry subset who 
received indacaterol–glycopyrronium OD (n=399) showed 
that 39.8% had an increase in FEV
1
 of 200 mL between 
baseline and week 26, 23.8% achieved 300 mL, and 13.1% 
had an increase of 400 mL.51
In three Phase III studies, LSM treatment differences 
in trough-FEV
1
 change from baseline to week 24 with 
umeclidinium–vilanterol 62.5/25 µg OD were 60–112 mL 
versus tiotropium 18 µg, 52 mL versus umeclidinium 62.5 µg, 
22 mL versus umeclidinium 125 µg (not statistically significant), 
90–95 mL versus vilanterol 25 µg, and 167 mL versus 
placebo.23,32,41 In two 12-week studies, umeclidinium–
vilanterol 62.5/25 µg produced greater increases in trough 
FEV
1
 versus individual components.33 In another two 12-week 
studies, umeclidinium–vilanterol 62.5/25 µg resulted in 
Table 2 Lung function: margin of efficacy of fixed combinations versus comparators in fully published studies
Reference and study Duration Treatment Trough FEV1 LSM  
(95% CI) treatment 
difference at end point, mL
Other lung-function  
parameters
IND–GLY
Bateman et al2 (SHINe) 26 weeks IND–GLY 110/50 µg OD vs 
Indacaterol 150 µg OD
Glycopyrronium 50 µg OD







IND–GLY provided significantly higher 
Fev1 AUC0–4 h and peak Fev1 compared 
with placebo, glycopyrronium, and 
tiotropium (all P0.01)




Fev1 at 60 minutes postdose significantly 
greater with IND–GLY than placebo 
throughout the 52-week treatment period 
(P0.001 at all time points); IND–GLY 
improved FvC versus placebo over the 
52-week treatment period (P0.001 at all 
time points)
Dahl et al37 (BeACON) 4 weeks IND–GLY 110/50 µg OD vs 
indacaterol 150 µg OD + 
glycopyrronium 50 µg OD
 
5 (NR; NS for superiority)
Fev1 AUC0–4 h (day 1 and week 4) similar 
between treatment groups
Mahler et al38 (BLAZe) 6 weeks IND–GLY 110/50 µg OD vs
Placebo




Fev1 AUC0–4 h postdose significantly higher 
for IND–GLY vs tiotropium and placebo 
at day 1 and week 6 (all P0.001)
vogelmeier et al39 
(ILLUMINATe)
26 weeks IND–GLY 110/50 µg OD vs 
SFC 50/500 µg BID
 
103a (65–141)
week 26 Fev1 AUC0–12 h significantly 
higher with IND–GLY than with SFC 
(treatment difference 138 mL, 95% 
CI 0.1–0.176; P0.0001)
wedzicha et al40 (SPARK) 64 weeks IND–GLY 110/50 µg OD vs
Glycopyrronium 50 µg OD





Beeh et al35 (BRIGHT) 3 weeks IND–GLY 110/50 µg OD vs





At day 21, mean treatment differences 
in trough IC, Fev1, and FVC significantly 
higher for IND–GLY vs placebo (190, 
200, and 280 mL, respectively) and 
vs tiotropium (150, 100, and 110 mL, 
respectively)
Buhl et al25 (QUANTIFY) 26 weeks IND/GLY 110/50 µg OD vs  
tiotropium 18 µg OD + 




IND–GLY increased predose FvC vs 
tiotropium + formoterol at week 26  
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LAMA–LABA Fev1 and patient-reported outcomes
Table 2 (Continued)
Reference and study Duration Treatment Trough FEV1 LSM  
(95% CI) treatment 
difference at end point, mL
Other lung-function  
parameters
Zhong et al24  
(LANTeRN)
26 weeks IND–GLY 110/50 µg OD vs 
SFC 50/500 µg BID
 
72a (40–104)
Improvements in trough Fev1 with 
IND–GLY vs SFC observed at day 1 
(Δ=43 mL) and reaching steady state 
by week 12 (Δ=78 mL, both P0.001). 
Improvements in Fev1 AUC0–4 h at day 1/ 
week 26 with IND–GLY vs SFC 
(Δ=65/122 mL, respectively). Peak Fev1 
higher at day 1/week 26 with IND–GLY 
vs SFC (P0.001). Trough FvC higher 
for IND–GLY vs SFC (P0.001). 
Improvements in peak FvC (over the 
first 4 hours) with IND–GLY vs SFC at 
day 1/week 26 (all P0.001)
wedzicha et al26  
(FLAMe)
52 weeks IND–GLY 110/50 µg OD vs 
SFC 50/500 µg BID
 
62a (NR)
Change from baseline in Fev1 AUC0–12h 
(measured in a subgroup of 556 
patients) was significantly greater with 
IND–GLY vs SFC at week 52  
(Δ=110 mL, P0.001)
UMEC–VI
Donohue et al41 24 weeks UMeC–vI 62.5/25 µg OD vs
Umeclidinium 62.5 µg OD






Improvements in trough FvC change 
from baseline observed at day 169 for 
UMeC–vI 62.5/25 µg, UMeC 62.5 µg, and 
vI 25 µg vs placebo (248 mL, 175 mL, and 
105 mL; all P0.002)
Decramer et al23 (study 1) 24 weeks UMeC–vI 125/25 µg ODc
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD





Mean 0- to 6-hour Fev1 on day 168 
for UMEC–VI (both doses) significantly 
improved vs tiotropium 18 µg
Decramer et al23 (study 2) 24 weeks UMeC–vI 125/25 µg ODc
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD




22 (-27 to 72)
Mean 0- to 6-hour Fev1 on day 168 for 
both doses of UMeC/vI improved vs 
tiotropium 18 µg (nominal P-values)
Maleki-Yazdi et al32 24 weeks UMeC–vI 62.5/25 µg OD vs 
tiotropium 18 µg OD
Change from baseline:
112a (81–144)
weighted mean Fev1 over 0–6 hours 
postdose at day 168 improved for 
UMeC–vI vs tiotropium (105 mL, 95% CI 
0.071–0.14; P0.001)
Maltais et al33 (study 417) 12 weeks UMeC–vI 125/25 µg ODc
 
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD
vilanterol 25 µg OD






Trough Fev1 numerically improved with 
UMeC–vI 125/25 µg and UMeC–vI 
62.5/25 µg compared with placebo from 
day 2 to week 12
Maltais et al33 (study 418) 12 weeks UMeC–vI 125/25 µg ODc
 
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD
vilanterol 25 µg OD






Trough Fev1 improved with UMeC–vI 
125/25 µg and UMeC–vI 62.5/25 µg 
compared with placebo (P0.001) from 
day 2 to week 12
Donohue et al27  
(study 2114930)
12 weeks UMeC–vI 62.5/25 µg OD vs 
SFC 50/250 µg BID
Change from baseline:
74a (38–110)
Fev1 significantly improved for UMEC–VI 
vs SFC at all time points on day 84 
(except 18 hours); significantly greater 
improvement in LSM trough Fev1 from 
baseline for UMeC–vI vs SFC on day 85 
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Reference and study Duration Treatment Trough FEV1 LSM  
(95% CI) treatment 
difference at end point, mL
Other lung-function parameters
Donohue et al27 (study 
2114951)
12 weeks UMeC–vI 62.5/25 µg OD vs 
SFC 50/250 µg BID
Change from baseline:
101a (63–139)
Fev1 significantly improved for UMEC–VI 
vs SFC at all time points on day 84; 
significantly greater improvement in LSM 
trough Fev1 from baseline for UMeC–vI 
vs SFC on day 85 (treatment difference 
98 mL, P0.001)
TIO–OLO
Buhl et al30 (study 1237.5) 52 weeks TIO–OLO 2.5/5 µg ODc
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD
Tiotropium 5 µg OD
Tiotropium 2.5 µg OD





Improvements observed for Fev1 values 
on all test days over each of the 52-week 
studies; responses in trough FvC and FvC 
AUC0–3 h over 24 weeks consistent with 
the primary end points
Buhl et al30 (study 1237.6) 52 weeks TIO–OLO 2.5/5 µg ODc
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD
Tiotropium 5 µg OD
Tiotropium 2.5 µg OD





Improvements observed for Fev1 values 
on all test days over each of the 52-week 
studies; responses in trough FvC and FvC 
AUC0–3 h over 24 weeks consistent with 
the primary end points
Beeh et al31 (vIvACITO) 6 weeks TIO–OLO 2.5/5 µg ODc
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD
Tiotropium 5 µg OD








Significant improvement in FEV1 AUC0–24 h  
and greater improvement in 24-hour 
Fev1 profile for both TIO–OLO doses vs 
placebo and monotherapies at 6 weeks; 
similar pattern of response for FvC, FRC, 
and residual volume
ACL–FORM
Singh et al28 (ACLIFORM-
COPD)
24 weeks ACL–FORM 400/6 µg BIDc
ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID
Aclidinium 400 µg BID
Placebo





Fast onset of action of both ACL–FORM  
doses on day 1, with significant 
improvements in bronchodilation vs 
placebo at 5 minutes postdose
D’Urzo et al29 
(AUGMeNT)
24 weeks ACL–FORM 400/6 µg BIDc
ACL–FORM 400/12 µg 
BID vs
Formoterol 12 µg BID
Aclidinium 400 µg BID
Placebo






ACL–FORM (both doses) associated 
with significant changes from baseline 
in peak Fev1 at day 1 and week 24 
(P0.0001 all comparisons); rapid 
bronchodilation occurred with significant 
Fev1 improvements 5 minutes postdose 
(P0.0001)
Notes: Treatment once daily unless stated otherwise. aSignificant treatment difference; bFev1 AUC0–4 h; 
cdose not approved for use (ACL–FORM, dose not approved in eU); 
destimated from figure.
Abbreviations: ACL–FORM, aclidinium–formoterol; AUC0–3 h, area under the plasma concentration-time curve from 0 to 3 hours; AUC0–4 h, area under the (plasma 
concentration–time) curve from 0 to 4 hours; AUC0–12 h, area under the (plasma concentration–time) curve from 0 to 12 hours; AUC0–24 h, area under the (plasma 
concentration–time) curve from 0 to 24 hours; BID, bis in die (twice daily); CI, confidence interval; FEV1, forced expiratory volume in 1 second; FvC, forced vital capacity; 
FRC, functional residual capacity; IC, inspiratory capacity; IND–GLY, indacaterol–glycopyrronium; LSM, least-squares mean; NR, not reported; NS, not significant; OD, once 
daily; OL, open-label; SFC, salmeterol/fluticasone combination; TIO–OLO, tiotropium–olodaterol; UMEC–VI, umeclidinium–vilanterol.
significant improvements in FEV
1
 0–24 hours and trough 
FEV
1
 compared with 50/250 µg BID.27
At week 24 of the two 1-year studies, tiotropium– 
olodaterol 5/5 µg OD increased trough FEV
1
 by 82–88 mL 
versus olodaterol 5 µg and by 50–71 mL versus tiotropium 
5 µg.30 A 6-week incomplete crossover study showed 
improvements in 24-hour lung function with tiotropium–
olodaterol 5/5 µg versus components or placebo.31
Aclidinium–formoterol (400/12 µg BID) increased 
week 24 trough FEV
1
 significantly versus placebo (143 mL) 
and formoterol (85 mL) in the ACLIFORM study, but 
the smaller difference (~25 mL) versus aclidinium BID was 
not statistically significant.28 Similar results were observed 
in the AUGMENT trial, with a significant difference 
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LAMA–LABA Fev1 and patient-reported outcomes
Symptoms
Improvements in dyspnea and other symptoms were 
seen with fixed-dose LABA–LAMA therapies versus 
monotherapies and for indacaterol–glycopyrronium OD 
versus SFC BID. (Table 3, Figure 2).2,24,25,38,39 Indacaterol–
glycopyrronium significantly improved transition dyspnea 
index (TDI) scores in SHINE and ILLUMINATE versus 
placebo, open-label tiotropium, and SFC.2,39 In BLAZE, 
indacaterol–glycopyrronium significantly improved self-
administered computerized total TDI score versus placebo 
(LSM treatment difference 1.37, P0.001) and blinded 
tiotropium (LSM treatment difference: 0.49, P=0.021).38 
The proportion of patients achieving the MCID (1-point) 
for TDI score was also significantly increased versus blinded 
 
Table 3 Symptoms: margin of efficacy of fixed combinations versus comparators in published studies
Reference  
and study 
Duration Treatment Treatment difference at end point






Bateman et al2 
(SHINe)
26 weeks IND–GLY 110/50 µg OD vs
Indacaterol 150 µg OD
Glycopyrronium 50 µg OD












Diary data (values vs placebo): % days with 
no daytime symptoms, +3.05b; % days able to 
perform usual daily activities, +11.48b–e; % nights 
without awakenings, +10.01b,c
Dahl et al36 
(eNLIGHTeN)







Total daily symptom score, -0.573b; % days 
with no daytime symptoms, +5.3b, % days able 
to perform usual daily activities, +8.1b; % nights 
without awakenings, +6.3
Dahl et al37 
(BeACON)
4 weeks IND–GLY 110/50 µg OD vs 
indacaterol 150 µg OD +






Total daily symptom score,
0.07 (-0.24, 0.39)
Mahler et al38 
(BLAZe)
6 weeks IND–GLY 110/50 µg OD vs 








Diary data (vs placebo and tiotropium):
Total daily symptom score, -0.72b and -0.03;  
% days with no daytime symptoms, +3.5b  
and +1.5; % nights with no awakenings, 5.6b and 





26 weeks IND–GLY 110/50 µg OD vs 






Differences in scores for most symptoms NS 
between treatment groups
% days with no daytime symptoms, +2.50b
Beeh et al35  
(BRIGHT)
3 weeks IND–GLY 110/50 µg OD vs 






Diary data, mean daily symptom score vs 
baseline:
IND–GLY -0.64, tiotropium -0.43,
placebo -0.19
Buhl et al25 
(QUANTIFY)
26 weeks IND–GLY 110/50 µg OD vs 
tiotropium 18 µg OD +




7.2 (1.17 risk 
ratio)b
LSM treatment difference in SGRQ-C symptom 
score IND–GLY vs tiotropium + formoterol 
(-1.31 [95% CI -3.49, 0.86])
Zhong et al24 
(LANTeRN)
26 weeks IND–GLY 110/50 µg OD vs 





Improvements in TDI focal score at weeks 12 
and 26 similar between IND–GLY and SFC
Similar improvement in SGRQ total score 
between IND–GLY and SFC at weeks 12 and 26
Symptoms, rescue medication use and total 
COPD assessment test scores at week 26 
comparable for IND–GLY and SFC
UMEC–VI
Donohue et al41 24 weeks UMeC–vI 62.5/25 µg OD vs 
umeclidinium 62.5 µg OD
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Decramer et al23 
(study 1)
24 weeks UMeC–vI 125/25 µg ODf
UMeC–vI 62.5/25 µg OD vs 
tiotropium 18 µg OD






Decramer et al23 
(study 2)
24 weeks UMeC–vI 125/25 µg ODf
UMeC–vI 62.5/25 µg OD vs 
tiotropium 18 µg OD







et al27  
(study 2114930)
12 weeks UMeC–vI 62.5/25 µg OD vs 
SFC 50/250 µg BID 0.3 (-0.2, 0.7) NR NR
Donohue  
et al27  
(study 2114951)
12 weeks UMeC–vI 62.5/25 µg OD vs 
SFC 50/250 µg BID 0.3 (-0.1, 0.8) NR NR
Maltais et al33 
(study 417)
12 weeks
UMeC–vI 125/25 µg ODf
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD







exercise dyspnea scale (Borg), changes from 
baseline vs placebo:
-0.25 (-0.57 to 0.07)f
-0.05 (-0.37 to 0.27)
-0.16 (-0.61 to 0.3)
-0.13 (-0.58 to 0.33)
0.39 (-0.01 to 0.79)
Maltais et al33 
(study 418)
12 weeks
UMeC–vI 125/25 µg ODf
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD







exercise dyspnea scale (Borg), change from 
baseline vs placebo:
-0.34 (-0.76 to 0.03)f
-0.36 (0.67 to -0.05)b
-0.32 (-0.78 to 0.13)
-0.66 (-1.14 to -0.18)
-0.36 (-0.76 to 0.03)
TIO–OLO




52 weeks TIO–OLO 2.5/5 µg ODf
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD











Singh et al28 
(ACLIFORM-
COPD)
24 weeks ACL–FORM 400/6 µg BIDf
ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID













ACL–FORM 400/12 µg 
BID vs
Formoterol 12 µg BID












ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID












D’Urzo et al29 
(AUGMeNT)
24 weeks ACL–FORM 400/6 µg BIDf
ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID
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ACL–FORM 400/6 µg BIDf
ACL–FORM 400/12 µg 
BID vs 
Formoterol 12 µg BID












ACL–FORM 400/6 µg BIDf
ACL–FORM 400/12 µg 
BID vs
Formoterol 12 µg BID








early-morning symptoms,  




Notes: Treatment once daily unless stated otherwise. aTDI responders had improvement 1 unit in TDI score. bSignificant treatment difference. Significant treatment 
difference versus cindacaterol, dglycopyrronium or etiotropium (values NR). fDose not approved for use (ACL–FORM, dose not approved in eU). gvalues in parentheses are 
differences expressed in percentage points (not percentage differences).
Abbreviations: ACL–FORM, aclidinium–formoterol; BID, bis in die (twice daily); CI, confidence interval; E-RS, Evaluating Respiratory Symptoms; IND–GLY, indacaterol–
glycopyrronium; LSM, least-squares mean; NR, not reported; NS, not significant; OR, odds ratio; SAC, self-administered, computerized; SFC, salmeterol–fluticasone 
combination; SGRQ-C, St George’s Respiratory Questionnaire – COPD; TIO–OLO, tiotropium–olodaterol; TDI, transition dyspnea index; UMeC–vI, umeclidinium–
vilanterol.
tiotropium in BLAZE (OR 1.78, P0.05) and versus 
SFC in ILLUMINATE (OR 1.56, P0.05; Figure 2).2,39 
In QUANTIFY, a similar reduction in dyspnea was observed 
with indacaterol–glycopyrronium versus tiotropium + 
formoterol, and significantly more patients achieved 
clinically relevant improvements in TDI total score with 
indacaterol–glycopyrronium (49.6%) versus tiotropium + 
formoterol (42.4%, P=0.033).25
In LANTERN, a comparable improvement with 
indacaterol–glycopyrronium OD and SFC BID was dem-
onstrated for TDI focal score and St George’s Respiratory 
Questionnaire (SGRQ) total score from baseline after 
26 weeks; the percentage of patients achieving the MCID for 
both end points was higher with indacaterol–glycopyrronium 
versus SFC.24 Compared with its component monotherapies, 
indacaterol–glycopyrronium was associated with numerical 
improvements in TDI score and percentage of TDI responders 
at week 26 in SHINE.2 At week 12, improvement in TDI 
score with indacaterol–glycopyrronium was significantly 
greater than with glycopyrronium (LSM treatment difference 
0.41, P=0.03).
Three indacaterol–glycopyrronium OD studies evaluated 
patient-diary data and reported significantly improved symp-
tom scores versus indacaterol, glycopyrronium, tiotropium, 
or placebo (Table 3).2,36,38 In the shorter BRIGHT trial, change 
in mean daily symptom score from baseline to week 3 was 
numerically greater for indacaterol–glycopyrronium versus 
tiotropium and placebo.35 In ILLUMINATE, differences in 
scores for most symptoms were comparable for indacaterol–
glycopyrronium and SFC BID.39
In three 24-week studies, umeclidinium–vilanterol 
62.5/25 µg OD significantly improved TDI focal and 
Shortness of Breath with Daily Activity (SOBDA) scores 
versus placebo, with numerical improvements versus mono-
components and tiotropium.23,41 The proportion of patients 
achieving the MCID for TDI score was significantly increased 
in patients receiving umeclidinium–vilanterol versus placebo 
(OR 2, P0.001) and vilanterol (OR 1.4, P0.05)41 in one 
study (Figure 2).23 LSM changes from baseline to week 24 
in SOBDA scores were clinically significant (0.1 unit) for 
umeclidinium–vilanterol, vilanterol 25 µg, umeclidinium 
62.5 and 125 µg, and tiotropium 18 µg.23,41 SOBDA responder 
rates were reported for one trial, and were significantly 
higher for umeclidinium–vilanterol (OR 1.8, P0.01) and its 
monocomponents (umeclidinium 52.5 µg OR 1.7, P0.01; 
vilanterol 25 µg OR 1.6, P0.05) versus placebo. In two 
12-week studies, there was no significant difference in TDI 
focal scores between umeclidinium–vilanterol 62.5/25 µg 
and salmeterol–fluticasone propionate 50/250 µg.27 Exercise-
associated dyspnea (Borg) was reduced with umeclidinium–
vilanterol 62.5/25 µg compared with placebo in one of two 
studies; active–placebo differences were not significant for 
the individual components.33 In combined results from two 
1-year studies, tiotropium–olodaterol OD increased TDI total 
score versus monocomponents (week 24) by approximately 
0.4 points with the higher dose and by a similar margin 
(0.3–0.4 points) with the lower dose.30
Symptoms were evaluated using a number of end points 
in the two 24-week aclidinium–formoterol BID studies.28,29 
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Figure 2 Differences between monotherapy and combination bronchodilators or placebo in TDI patient-response rates in published studies.
Notes: (A) Indacaterol–glycopyrronium; (B) umeclidinium–vilanterol 62.5/25 µg; (C) aclidinium–formoterol 400/12 µg BID. TDI response was defined as improvement 
of 1 unit in TDI score. All treatments were once daily unless stated otherwise. *Significant treatment difference. aBateman et al;2 bself-administered computerized TDI;38 
cvogelmeier et al;39 dBuhl et al;25 eDonohue et al;41 fDecramer et al;23 gSingh et al;28 hD’Urzo et al.29
Abbreviations: BID, bis in die (twice daily); SFC, salmeterol–fluticasone propionate; TDI, transition dyspnea index.
BID achieved a significant, 1-point improvement versus 
placebo (and a higher proportion of TDI responders), but the 
differences versus the monotherapies were not significant. For 
Evaluating Respiratory Symptoms (E-RS) score, the combina-
tion was significantly better than placebo (both studies) and the 
monotherapies (one study). Aclidinium–formoterol 400/12 µg 
improved nighttime symptom scores versus placebo (one 
study) or aclidinium BID (one study); early morning symptom 
scores were improved versus placebo and aclidinium (both 
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LAMA–LABA Fev1 and patient-reported outcomes
Rescue-medication use
Rescue-medication usage provides a surrogate measure of 
symptom control, and was reported in most of the published 
indacaterol–glycopyrronium OD and umeclidinium– 
vilanterol OD Phase III trials (Table 4). Indacaterol– 
glycopyrronium treatment consistently led to significantly 
less rescue-medication use per day than LABA or LAMA 
monotherapy or LABA–inhaled corticosteroids in each 
trial with active comparators.2,26,35,38–40 In LANTERN, 
rescue-medication use was comparable between the 
indacaterol–glycopyrronium and SFC BID groups.24 Daily 
rescue-medication use was similar or numerically slightly 
lower with umeclidinium–vilanterol versus either umecli-
dinium or vilanterol monotherapy, significantly lower 
versus tiotropium in two of three trials, and significantly 
lower versus SFC in one of two trials.23,27,32,33,41 Rescue-
medication use remained at approximately two puffs/day with 
tiotropium–olodaterol OD over the course of 52 weeks; at the 
Table 4 Rescue-medication use: margin of efficacy of fixed combinations versus comparators in published studies
Reference and study Duration Treatment Rescue albuterol/salbutamol puffs/day 
change from baseline, LSM (95% CI) 
treatment difference at end point
IND–GLY
Bateman et al2 (SHINe) 26 weeks IND–GLY 110/50 µg OD vs
Indacaterol 150 µg OD
Glycopyrronium 50 µg OD





-0.96a (-1.29 to -0.62)
Dahl et al36 (eNLIGHTeN) 52 weeks IND–GLY 110/50 µg OD vs
Placebo -0.73a (NR)
Dahl et al37 (BeACON) 4 weeks IND–GLY 110/50 µg OD vs
Indacaterol 150 µg OD + 
glycopyrronium 50 µg OD
-0.04 (-0.35 to 0.28)
Mahler et al38 (BLAZe) 6 weeks IND–GLY 110/50 µg OD vs
Placebo
Tiotropium 18 µg OD
-1.43a (-1.72 to -1.13)
-0.45a (-0.74 to -0.16)
vogelmeier et al39 (ILLUMINATe) 26 weeks IND–GLY 110/50 µg OD vs
SFC 50/500 µg BID -0.39a (-0.71 to -0.06)
wedzicha et al40 (SPARK) 64 weeks IND–GLY 110/50 µg OD vs
Glycopyrronium 50 µg OD
Tiotropium 18 µg OD OL
-0.81a (NR)
-0.76a (NR)
Beeh et al35 (BRIGHT) 3 weeks IND–GLY 110/50 µg OD vs




Zhong et al24 (LANTeRN) 26 weeks IND–GLY 110/50 µg OD vs
SFC 50/500 µg BID -0.03 (-0.26 to 0.21)
wedzicha et al26 (FLAMe) 52 weeks IND–GLY 110/50 µg OD vs
SFC 50/500 µg BID -0.25a (-0.38 to -0.12)
UMEC–VI
Donohue et al41 24 weeks UMeC–vI 62.5/25 µg OD vs
Umeclidinium 62.5 µg OD
vilanterol 25 µg OD
Placebo
-0.6a (-1.0 to -0.1)
0.1 (-0.3 to 0.5)
-0.8a (-1.3 to -0.3)
Decramer et al23 (study 1) 24 weeks UMeC–vI 125/25 µg ODb
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD
vilanterol 25 µg OD
-0.7a (-1.2 to -0.1)
-0.3 (-0.8 to 0.3)
Decramer et al23 (study 2) 24 weeks UMeC–vI 125/25 µg ODb
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD
Umeclidinium 125 µg OD
-0.6 (-1.2 to 0)
-0.6 (-1.2 to 0)
Maleki-Yazdi et al32 24 weeks UMeC–vI 62.5/25 µg OD vs
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Reference and study Duration Treatment Rescue albuterol/salbutamol puffs/day 
change from baseline, LSM (95% CI) 
treatment difference at end point
Maltais et al33 (study 417) 12 weeks UMeC–vI 125/25 µg ODb
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD
vilanterol 25 µg OD
Differences from placebo:
-0.6a (-0.8 to -0.3)
-0.2 (-0.6 to 0.1)
-0.6a (-1 to -0.2)
-0.4a (-0.7 to 0)
Maltais et al33 (study 418) 12 weeks UMeC–vI 125/25 µg ODb
UMeC–vI 62.5/25 µg OD
Umeclidinium 62.5 µg OD
Umeclidinium 125 µg OD
vilanterol 25 µg OD
Differences from placebo:
-1.2a (-1.5 to -0.8)
-0.7a (-1.3 to -0.2)
-1.0a (-1.5 to -0.4)
-0.8a (-1.2 to -0.3)
Donohue et al27 (study 2114930) 12 weeks UMeC–vI 62.5/25 µg OD vs
SFC 50/250 µg BID 0 (-0.3 to 0.2)
Donohue et al27 (study 2114951) 12 weeks UMeC–vI 62.5/25 µg OD vs
SFC 50/250 µg BID -0.3a (-0.6 to -0.1)
TIO–OLO
Buhl et al30 (studies 1237.5 and 
1237.6 combined)
52 weeks TIO–OLO 2.5/5 µg ODb
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD




Singh et al28 (ACLIFORM-COPD) 24 weeks ACL–FORM 400/6 µg BIDb
ACL–FORM 400/12 µg 
BID vs
Formoterol 12 µg BID





D’Urzo et al29 (AUGMeNT) 24 weeks ACL–FORM 400/6 µg BIDb
ACL–FORM 400/12 µg 
BID vs
Formoterol 12 µg BID





Notes: Treatment once daily unless stated otherwise. aSignificant treatment difference; bdose not approved for use; cestimated from figure. Statistical analysis not reported.
Abbreviations: ACL–FORM, aclidinium–formoterol; BID, bis in die (twice daily); CI, confidence interval; IND–GLY, indacaterol–glycopyrronium; LSM, least-squares mean; NR, 
not reported; NS, not significant; OL, open-label; SFC, salmeterol–fluticasone combination; TIO–OLO, tiotropium–olodaterol; UMEC–VI, umeclidinium–vilanterol.
end of the studies, this was 0.3–0.4 puffs/day less than with 
olodaterol and 0.7–0.8 puffs/day less than with tiotropium.30 
In the two 24-week studies with aclidinium–formoterol 
400/12 µg BID, rescue-medication use was significantly 
lower compared with placebo and aclidinium BID, but not 
compared with formoterol.28,29
exacerbations
The effects of FDC therapy on exacerbation rates and time 
to first exacerbation are summarized in Table 5.
The effect of indacaterol–glycopyrronium OD on 
exacerbation rate was examined as the primary end point 
in both SPARK and FLAME, and exacerbation rates have 
also been reported from ILLUMINATE, LANTERN, and 
QUANTIFY.24–26,39,40,52 In SPARK, indacaterol–glycopyrronium 
significantly reduced rates of moderate-to-severe (pri-
mary end point, rate ratio 0.88; P=0.038) and all exacerbations 
(LSM treatment difference 0.85, P0.01) versus glycopyr-
ronium.40 Compared with open-label tiotropium, rates of 
moderate-to-severe exacerbations were 10% lower with 
indacaterol–glycopyrronium (P=0.096), and rates of all 
exacerbations were 14% lower (P0.01). In comparison with 
SFC BID in a post hoc analysis of data from ILLUMINATE, 
rates of moderate-to-severe exacerbations (rate ratio 0.8, not 
significant [NS]) and all exacerbations (rate ratio 0.69, NS) 
were numerically lower with indacaterol–glycopyrronium.52 
In LANTERN, indacaterol–glycopyrronium significantly 
reduced the rate of moderate or severe exacerbations by 
31% (P=0.048) over SFC.24 Furthermore, in the recent 
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LAMA–LABA Fev1 and patient-reported outcomes
(HR 0.5, P0.001),41 but not compared with vilanterol 25 
µg (HR 0.7, NS) or umeclidinium 125 µg (HR 1, NS).23
Time to first exacerbation was comparable for combina-
tion therapy versus tiotropium alone in two trials23 and sig-
nificantly greater in a third study (HR 0.5, P=0.044).32 In the 
combined results of the two 52-week studies with tiotropium–
olodaterol OD, there was only a “trend” for improvement in 
exacerbations with both doses of the combination versus the 
monotherapy components.30 Over the 24 weeks of the ACLI-
FORM study, using the health care resource-utilization defini-
tion of exacerbations, aclidinium–formoterol BID 400/12 µg 
was not significantly different from placebo or its separate 
components; with the EXACT (EXAcerbations of COPD 
Tool) definition, a significant difference was demonstrated 
versus placebo, but not compared with the components.28
Exacerbations were not reported as an efficacy outcome 
in the AUGMENT study.29
Health status
Indacaterol–glycopyrronium OD significantly improved 
health status, assessed using the SGRQ (Table 6). In SPARK, 
reduced the rates of all exacerbations (primary end point) 
by 11% (P=0.003) and of moderate-to-severe exacerbations 
by 17% (P0.001) compared with SFC; findings were 
consistently in favor of indacaterol–glycopyrronium when 
patients were analyzed according to their baseline disease 
characteristics, including baseline eosinophil count (2% 
or 2%).26 This study also found that compared with SFC, 
indacaterol–glycopyrronium was associated with longer times 
to first exacerbation, representing reduced risks of 16% for 
all exacerbations (P0.001), 22% for moderate-to-severe 
exacerbations (P0.001), and 19% for severe exacerba-
tions (P=0.046). Finally, QUANTIFY showed a comparable 
percentage of patients experiencing at least one moderate or 
severe exacerbation and a comparable time to first moderate 
or severe exacerbation between the two treatment groups 
(indacaterol–glycopyrronium vs tiotropium + formoterol).25
Currently, there are no studies evaluating exacerbation risk 
as a primary end point in patients receiving umeclidinium–
vilanterol OD. The data available from analysis of secondary 
end points indicate that umeclidinium–vilanterol signifi-
cantly increased time to first exacerbation versus placebo 
Table 6 Health status: margin of efficacy of fixed combinations versus comparators in published studies
Reference  
and study
Duration Treatment Treatment difference at end point
SGRQ total score, LSM (95% CI) % SGRQ responders (OR)
IND–GLY
Bateman et al2  
(SHINe)
26 weeks IND–GLY 110/50 µg OD vs
Indacaterol 150 µg OD
Glycopyrronium 50 µg OD










vogelmeier et al39 
(ILLUMINATe)
26 weeks IND–GLY 110/50 µg OD vs  
SFC 50/500 µg BID -1.24 (-3.33 to 0.85) 6.4 (1.32)
wedzicha et al40 
(SPARK)
64 weeks IND–GLY 110/50 µg OD vs
Glycopyrronium 50 µg OD
Tiotropium 18 µg OD OL
-1.9 to -2.8b (NR); all P0.01
-1.7 to -3.1b (NR); all P0.05
NR (1.28)
NR (1.29)
Buhl et al25 
(QUANTIFY)
26 weeks IND–GLY 110/50 µg OD vs 
tiotropium 18 µg OD + formoterol 
12 µg BID
-0.69 (-2.31 to 0.92) 4.5 (risk ratio 1.11)
Zhong et al24 
(LANTeRN)
26 weeks IND–GLY 110/50 µg OD vs  
SFC 50/500 µg BID -0.69 (-2.38 to 1) NR
wedzicha et al26 
(FLAMe)
52 weeks IND–GLY 110/50 µg OD vs  
SFC 50/500 µg BID -1.8a (NR) 1.3a (NR)
UMEC–VI
Donohue et al41 24 weeks UMeC–vI 62.5/25 µg OD vs
Umeclidinium 62.5 µg OD
vilanterol 25 µg OD
Placebo
Change from baseline:
-0.82c (-2.90 to 1.27)
-0.32c (-2.41 to 1.78)




Decramer et al23 
(study 1)
24 weeks UMeC–vI 125/25 µg ODd
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD




















































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1








Duration Treatment Treatment difference at end point
SGRQ total score, LSM (95% CI) % SGRQ responders (OR)
Decramer et al23  
(study 2)
24 weeks UMeC–vI 125/25 µg ODd
UMeC–vI 62.5/25 µg OD vs
Tiotropium 18 µg OD






Maleki-Yazdi et al32 24 weeks UMeC–vI 62.5/25 µg vs  
tiotropium 18 µg
Change from baseline:
-2.1a (-3.61 to -0.59) 7a (1.4)
Donohue et al27  
(study 2114930)
12 weeks UMeC–vI 62.5/25 µg OD vs  
SFC 50/250 µg BID 0.47 (-1.36 to 2.29) NR
Donohue et al27 
(study 2114951)
12 weeks UMeC–vI 62.5/25 µg OD vs  
SFC 50/250 µg BID -1.55 (-3.63 to 0.53) NR
TIO–OLO
Buhl et al30 (studies 
1237.5 and 1237.6 
combined)
52 weeks TIO–OLO 2.5/5 µg ODd
TIO–OLO 5/5 µg OD vs
Olodaterol 5 µg OD








Singh et al28 
(ACLIFORM-
COPD)
24 weeks ACL–FORM 400/6 µg BIDd
ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID
Aclidinium 400 µg BID
Placebo
Change from baseline:
-1.59 (-3.52 to 0.35)
-1.36 (-3.3 to 0.58)




D’Urzo et al29 
(AUGMeNT)
24 weeks ACL–FORM 400/6 µg BIDd
ACL–FORM 400/12 µg BID vs
Formoterol 12 µg BID









Notes: Treatment once daily unless stated otherwise. SGRQ response = SGRQ total score 4 units versus baseline. aSignificant treatment difference; brange of LSM 
differences in scores for weeks 12, 24, 38, 52, and 64 (95% CI not reported); cdifferences in LSM change from baseline to week 24; ddose not approved for use (ACL–FORM 
dose not approved in eU); e95% CI not reported; fOR not reported.
Abbreviations: ACL–FORM, aclidinium–formoterol; BID, bis in die (twice daily); CI, confidence interval; IND–GLY, indacaterol–glycopyrronium; LSM, least-squares mean; 
NR, not reported; OL, open-label; OR, odds ratio; SFC, salmeterol–fluticasone combination; SGRQ, St George’s Respiratory Questionnaire; TIO–OLO, tiotropium–
olodaterol; UMeC–vI, umeclidinium–vilanterol.
indacaterol–glycopyrronium improved SGRQ total score 
versus glycopyrronium (all P0.01) and open-label tiotro-
pium (all P0.05; 12–64 weeks).40 In SHINE, improvement 
in SGRQ with indacaterol–glycopyrronium was superior 
to open-label tiotropium (P=0.009) and placebo (P=0.002) 
and comparable to component monotherapies.2 In a 26-week 
study, indacaterol–glycopyrronium and SFC BID provided 
similar improvements in health status.39 However, in FLAME, 
significant improvements over time in SGRQ total score 
were observed for indacaterol–glycopyrronium compared 
with SFC, with treatment differences that ranged from -1.2 
points to -1.8 points over the time points measured between 
weeks 12 and 52 (all P0.01).26 The SGRQ responder rate for 
the MCID (reduction of 4 units from baseline)53 was also 
significantly greater with indacaterol–glycopyrronium versus 
SFC in FLAME (OR 1.3, P0.001)26 and versus glycopyr-
ronium (OR 1.62, P=0.00013) and open-label tiotropium 
(OR 1.48, P=0.0017) at all time points except week 64 in 
SPARK.40 In QUANTIFY, indacaterol–glycopyrronium was 
noninferior to tiotropium + formoterol for improvement in 
SGRQ score; the percentage of patients achieving a MCID was 
significantly in favor of indacaterol–glycopyrronium (50.1% 
vs 42.5%, P=0.038) in the per-protocol set.25 Similarly, in 
LANTERN comparable improvements with indacaterol–
glycopyrronium versus SFC were observed for all SGRQ 
analyses (weeks 12 and 26).24
Significant improvements in SGRQ total score mean 
change from baseline (P0.001) and percentages of 
SGRQ responders (OR 2, P0.001) were reported for 
umeclidinium–vilanterol 62.5/25 µg OD versus placebo 
in three 24-week studies.41 Across three of four trials, 
health-status improvement was not significantly differ-
ent for umeclidinium–vilanterol versus monotherapy with 
tiotropium, vilanterol, or umeclidinium (SGRQ total scores 
or percentage of SGRQ responders).23,41 The fourth trial 
reported significant improvement in SGRQ total score from 
baseline (P0.006) and percentage of SGRQ responders 
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LAMA–LABA Fev1 and patient-reported outcomes
tiotropium.32 Improvements in SGRQ from baseline were 
not significantly different between umeclidinium–vilanterol 
62.5/25 µg and salmeterol–fluticasone propionate 50/250 µg 
in two 12-week studies.27
In combined results from two 1-year studies, tiotropium–
olodaterol 5/5 µg OD significantly improved SGRQ total 
score at week 24 by 1.2 and 1.7 units versus its respective 
components. Proportions of SGRQ responders were signifi-
cantly increased for all the combination-versus-component 
comparisons, apart from tiotropium–olodaterol 2.5/5 µg 
versus tiotropium 2.5 µg. In the 24-week ACLIFORM 
and AUGMENT studies, aclidinium–formoterol BID 
improved SGRQ total score and percentage of responders 
significantly compared with placebo in one study, but did 
not achieve significant differences against its components 
in either study.28,29
Safety
To date, the most extensive safety data available for FDC 
bronchodilators comes from indacaterol–glycopyrronium OD 
trials. Overall, indacaterol–glycopyrronium was well tolerated 
across the studies, and had a similar safety profile to placebo 
in individual trials and analyses of pooled data.2,36,39,40,54–56 The 
incidence of adverse events (AEs) and serious AEs (SAEs) 
reported with indacaterol–glycopyrronium treatment was 
comparable to that of placebo, indacaterol, glycopyrronium, 
tiotropium (± formoterol) or SFC BID.2,24–26,36,39,40 Interest-
ingly, the FLAME trial reported a significant reduction in the 
incidence of pneumonia with indacaterol–glycopyrronium 
compared with SFC (3.2% vs 4.8%, respectively; P=0.02).26 
In an analysis of pooled data from 11,404 patients, the HR 
for indacaterol–glycopyrronium versus placebo showed 
no significant increase in the overall risk for death (HR 
[95% CI] 0.93 [0.34–2.54]), cardiocerebrovascular events 
(0.6 [0.29–1.24]), major adverse cardiovascular events 
(MACEs; 1.04 [0.45–2.42]), pneumonia (1.1 [0.54–2.25]), 
COPD exacerbations (0.6 [0.4–0.91]), or atrial flutter/fibril-
lation (1.03 [0.49–2.18]).54
Over 24 weeks, umeclidinium–vilanterol 62.5/25 µg OD 
was well tolerated, and the incidence of AEs and serious 
AEs was similar for combination therapy versus placebo and 
monocomponents.41,57 The rate of class-effect AEs associated 
with anticholinergic (eg, dry mouth) and BA (eg, tachycardia) 
agents was similar to that observed for placebo.41,57 In two 
12-week studies, umeclidinium–vilanterol 62.5/25 µg and 
SFC 250/50 µg were both well tolerated and had similar 
AE profiles.27 In a pooled analysis of data from eight trials 
of umeclidinium–vilanterol 62.5/25 µg and 125/25 µg, no 
increased risk of MACE was observed with active treatment 
versus placebo.58 Small numerical imbalances in cardiac 
ischemia were reported in some studies, but not others. As the 
imbalances were not dose-related, they were not considered 
drug-related. The incidence of cardiovascular AEs of special 
interest was comparable for umeclidinium–vilanterol, mono-
components, and placebo.
In the two 1-year tiotropium–olodaterol OD studies, 
the frequency of AEs was largely comparable between the 
combination- and individual component-treatment groups. 
The rates of MACE and cardiac events did not differ 
significantly between the combination and the individual 
component groups.30 Similarly, AE reporting (including 
MACE and Holter monitoring) in the two aclidinium–
formoterol BID studies was generally comparable across all 
treatment groups.28,29
In a 2013 preliminary report from a retrospective cohort 
study of mortality in more than 5,000 patients with COPD, 
LAMA–LABA combination therapy reduced both all-cause 
(HR 0.53 [95% CI 0.34–0.84]) and cardiovascular mortality 
(HR 0.39 [95% CI 0.17–0.9]).59 Reductions in both mortal-
ity types were also observed with LAMA–LABA–inhaled 
corticosteroids, LABA–inhaled corticosteroids, and LAMA-
only treatment.
Discussion
We identified 23 published Phase III RCTs of FDC 
bronchodilators in COPD. The data demonstrated that 
fixed-dose LAMA–LABA combinations significantly 
improved lung function compared with component mono-
therapies or single agents.2,23,30–32,35,36,39–41 Indacaterol–
glycopyrronium OD, umeclidinium–vilanterol OD, and 
tiotropium–olodaterol OD also provided significant 
improvements over component monotherapies and/or 
tiotropium in several PROs.2,23,30,32,35,38,40,41 Compared with 
its components, aclidinium–formoterol BID improved symp-
toms (one study),28 but did not improve health status.28,29 
Indacaterol–glycopyrronium and umeclidinium–vilanterol 
significantly improved lung function compared with SFC 
BID.26,27,39 Indacaterol–glycopyrronium also improved exac-
erbation rates in LANTERN and FLAME (Table 6), reduced 
dyspnea in ILLUMINATE, and led to reductions in use of 
rescue medication in ILLUMINATE and FLAME compared 
with SFC.24,26,27,39 The safety profiles of the FDC agents were 
similar to placebo and incidence of pneumonia significantly 
reduced with indacaterol–glycopyrronium versus SFC in 
FLAME.2,23,26,30,32,36,39–41,54,56
Several studies have examined the relationship between 
improvements in lung function following LABA or LAMA 
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such as SGRQ total score, TDI, exacerbation rate, and 
rescue-medication use. However, although significant or 
clinically relevant correlations appear at group levels, they 
tend to be only moderate, weak, or too weak to be useful at 
individual levels.16–19,21 This may be because some patients 
have very poor health despite only mild lung-function impair-
ments or vice versa.17 Indeed, the health impact of COPD 
is not necessarily mediated entirely through expiratory air-
flow limitation; a better correlate may instead be exercise 
performance.17 The analyzed studies may also have been too 
short in duration to capture meaningful changes in exacerba-
tions or health status, and only a few studies were available 
for some outcomes.18 Finally, the Hawthorne effect may also 
have played a role, as changes in FEV
1
 of 0 still resulted in a 
2.5-point reduction in SGRQ score in some cases.18
Likewise, in trials of combination-bronchodilator therapy 
versus components, improvement in FEV
1
 was not always 
mirrored by improved PROs. For example, significant 
improvement in dyspnea for umeclidinium–vilanterol OD 
versus monocomponents occurred only for vilanterol (in one 
of three trials), despite improvements in FEV
1
.23,41 Possible 
reasons for this include insufficient sensitivity/specificity in 
instruments assessing PROs. Additionally, such measure-
ments as inspiratory capacity may be more strongly related 
to dyspnea and COPD pathophysiology than FEV
1
.60 There-
fore, it may be useful to examine correlations between other 
outcomes instead, in larger sample sizes or longer-duration 
studies. Findings may still be somewhat limited though, as 
these end points are often only secondary, meaning power 
may be lacking.
Patient-selection criteria represent an important limi-
tation of RCTs. Most trials recruit subjects from highly 
selective populations likely to represent less than 5% of 
“real-life” patients. As such, the extrapolation of RCT data 
is limited.61 Populations are generally chosen to demonstrate 
the primary end point (usually lung function). Clinical trial 
participants tend to be less symptomatic than general patient 
populations, and clinical trials may exclude patients likely 
to benefit the most from treatment (as a maximum level 
of benefit may be reached sooner). Additionally, the most 
symptomatic patients in control arms may discontinue study 
treatment to obtain greater symptom relief. In contrast, 
real-life studies are likely to involve broader populations 
and treat each study arm to a similar level. Roche et al sug-
gested a new framework to categorize the approach taken 
in clinical trials from highly controlled efficacy RCT man-
agement to usual clinical care.61 The positioning of studies 
on this scale can be useful as a descriptive classification.61 
Future COPD trials may need to include more real-life 
patient populations and ecology of care. In addition, 
composite end points, such as lack of exacerbations and 
improved health status, may provide greater insight into 
the true benefits of treatment.
Additional studies of fixed-combination bronchodilators 
are needed to characterize further the relationship between 
FEV
1
 and PROs with these agents, as well as defining optimal 
strategies for their use in clinical practice. Should therapy 
be initiated with a single bronchodilator and then stepped up 
to a LABA–LAMA combination and/or triple therapy with 
LABA–LAMA plus another agent as needed, or should treat-
ment commence with a LABA–LAMA in certain patients?
In conclusion, our review of a systematic literature search 
indicates that fixed-dose LABA–LAMA combinations 
significantly improved lung function compared with their 
component monotherapies. In general, LABA–LAMA com-
binations also improved other outcomes, including symptoms 
and health status, compared with the monotherapies, although 
some discrepancies between lung function and PROs were 
apparent. Further research is needed to explore the relation-
ship between lung-function outcomes and PROs in patients 
receiving LABA–LAMA combinations.
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Table S1 Search strategy and results for published manuscripts and congress abstracts
Search number Search terms Number of records
S1 MeSH.eXACT.eXPLODe (“Bronchodilator Agents”) AND MeSH.eXACT.eXPLODe 
(“Drug Combinations”)
821a
S2 “Fixed-dose combination” OR “Fixed dose combination” OR “Fixed-dose long-acting 
combination” OR “Fixed dose long-acting combination” OR “Fixed-dose combinations” 
OR “Fixed dose combinations” OR “Fixed-dose long-acting combinations” OR “Fixed dose 
long-acting combinations” OR “fixed combination” OR “fixed combinations” OR “LABA/
LAMA” OR “LAMA/LABA” OR “dual bronchodilator” OR “dual bronchodilators” OR 
“dual bronchodilation” OR “dual-acting bronchodilator” OR “dual-acting bronchodilators” 
OR “dual-acting bronchodilation” OR “QvA149” OR “QvA-149” OR “QvA 149” 
OR “glycopyrronium/indacaterol” OR “indacaterol/glycopyrronium” OR “Anoro” OR 
“umeclidinium/vilanterol” OR embase.eXACT (“glycopyrronium bromide plus indacaterol”)
6,959b
S3 MeSH.eXACT.eXPLODe (“Pulmonary Disease, Chronic Obstructive”) OR “chronic 
obstructive pulmonary disease” OR “COPD” OR “Chronic Obstructive Lung Disease” OR 
“Chronic Obstructive Airway Disease”
90,402b
S4 (S1 OR S2) AND S3 444a
Notes: aDuplicate citations removed from result count; bresult count includes duplicate citations. ProQuest search, including Biosis, Biosis previews, embase, and Medline 
databases. Searches were limited to publications from January 1, 2006 to July 31, 2014 and english-language articles.
Abbreviations: eXACT, eXAcerbations of COPD Tool; eXPLODe, terms indexed as subterms included; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic 
antagonist; MeSH, Medical Subject Headings.
Table S2 Congress abstract search strategy and results
Congress abstracts searched • Annual Congress of the european Respiratory Society
• Annual International Conference of the American Thoracic Society
• Annual winter Meeting of the British Thoracic Society
• Biennial International Multidisciplinary Conference on Chronic Obstructive Pulmonary Disease
• Biennial world Conference of the International Primary Care Respiratory Group
• CHeST
• Annual Congress of the Asian Pacific Society of Respirology
Search terms “Fixed-dose combination” OR “Fixed dose combination” OR “Fixed-dose long-acting combination” OR “Fixed dose 
long-acting combination” OR “Fixed-dose combinations” OR “Fixed dose combinations” OR “Fixed-dose long-acting 
combinations” OR “Fixed dose long-acting combinations” OR “fixed combination” OR “fixed combinations” OR 
“LABA/LAMA” OR “LAMA/LABA” OR “dual bronchodilator” OR “dual-bronchodilator” OR “dual-bronchodilators” 
OR “dual-bronchodilation” OR “dual bronchodilators” OR “dual bronchodilation” OR “dual-acting bronchodilator” 
OR “dual-acting bronchodilators” OR “dual-acting bronchodilation” OR “dual acting bronchodilator” OR “dual 
acting bronchodilators” OR “dual acting bronchodilation” OR “QvA149” OR “QvA-149” OR “QvA 149” OR 
“glycopyrronium/indacaterol” OR “indacaterol/glycopyrronium” OR “Anoro” OR “umeclidinium/vilanterol” OR 
“glycopyrronium bromide plus indacaterol” OR “glycopyrronium plus indacaterol”
Number of records 285
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